Trial Details
RecruitingBasic Information
| Clinical ID | c2112 |
|---|---|
| Identifier | NCT06226883 |
| Trial Title | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 2 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Inflammatory Bowel Diseases;Crohn's Disease |
| Interventions | Drug: Placebo;Drug: MORF-057 |
Participant Information
| Sponsor | Morphic Therapeutic, Inc |
|---|---|
| City | - |
| Country/Region | United States;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Hungary;India;Italy;Kazakhstan;Latvia;Mexico;Poland;Romania;Serbia;Slovakia;Spain |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, ELDER, OLDER_ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |